HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California Cosmetics Bill Aims To Eliminate Half The Conventional Preservatives Recognized By FDA

Executive Summary

The Toxic Free Cosmetics Act would make products adulterated under California law if they contain asbestos, lead or any one of a slew of intentionally added ingredients, most of them preservatives. The bill could be industry’s biggest legislative battle over the 2019-2020 period.

You may also be interested in...



California’s Proposed Toxic-Free Cosmetics Act Revived As 2020 Begins

Cosmetic products in California that contain at least one of more than a dozen listed ingredients or contaminants – or any others selected by the health department going forward – would be adulterated and thus unlawfully marketed under the proposed Toxic-Free Cosmetics Act.

California’s Proposed Toxic Free Cosmetics Act Put On Ice After Industry Lobbying Blitz

The bill, which would deal a serious blow to industry’s preservatives palette and prohibit any trace of lead in cosmetics, failed to advance out of committee April 9, roughly one week after the Personal Care Products Council and other industry reps descended on Sacramento to lobby against the measure.

ICMAD: Federal Cosmetics Legislation Without National Uniformity Not In Industry’s Interest

If the goal of bills like the proposed Personal Care Products Safety Act is to shore up consumers’ trust in the safety of cosmetic products, national uniformity is an indispensable component, says eos Products President Sanjiv Mehra, chairman of ICMAD’s board.

Related Content

Topics

UsernamePublicRestriction

Register

RS148673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel